Clinical trials: Oligometastatic Disease
Prostate Cancer
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic…
- Trial name
- NCT03556904
- Testing
- Ablative Radiation Therapy, Hormone therapy or chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan Rogel Cancer Center
NSCLC/Oligometastatic Cancer (Single Lung Lesion)
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
This is a phase II, non-randomised study examining the safety of treating high risk centrally located non-small cell lung cancer (NSCLC) tumours and single pulmonary oligometastatic lesions using radiation therapy (RT), for…
- Trial name
- SOURCE Lung (NCT04375904)
- Testing
- Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)
- Where
- 2 sites in Ireland
- Volunteers
- 68 people
- Sponsor
- Cancer Trials Ireland
Renal Cell Carcinoma, RCC
A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma
Study the efficacy and toxicity of SABR treatment for oligometastatic/oligoprogressive renal cell carcinoma; investigate the effectiveness and safety of SABR combined with targeted immunotherapy; conduct stratified analysis to…
- Conditions
- Renal Cell Carcinoma, RCC, Kidney Cancer
- Trial name
- NCT06585878
- Testing
- Stereotactic Ablative Radiotherapy (SABR)
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
Plasma Multi - Omics Detection for Evaluating Efficacy and Recurrence Risk in Oligometastatic Colorectal Cancer Conversion Therapy
This prospective study (PMEIRR-OCCCT) evaluates the utility of plasma multi-omics-including circulating tumor DNA (ctDNA), cell-free RNA (cfRNA), proteomics, and metabolomics-in assessing response to conversion therapy and…
- Trial name
- PMEIRR - OCCCT (NCT07492238)
- Testing
- Plasma Multi - omics Detection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiujuan Qu
Prostate Cancer Recurrent, Prostate Cancer
SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience
Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between…
- Conditions
- Prostate Cancer Recurrent, Prostate Cancer, Lymph Node Metastases
- Trial name
- NCT03604211
- Testing
- Cyberknife Radiation Therapy
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- Kantonsspital Graubünden
Cancer
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer is the second leading cause of death in the United States, with approximately 90% of deaths resulting from patients with metastatic spread.
- Trial name
- NCT00463060
- Testing
- sunitinib malate (Sutent), radiotherapy
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Gynecologic Cancer, Skin Cancer
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
- Conditions
- Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- OligoRARE (NCT04498767)
- Testing
- Stereotactic body radiotherapy, Palliative RT
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic…
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
- Trial name
- NCT07824856
- Testing
- CT-guided percutaneous local ablation, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Gastric Neoplasm
Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
Efficacy and safety of fruquintinib in combination with sintilizumab and SBRT in the treatment of oligonadenocarcinoma progression in the stomach or gastroesophageal junction
- Trial name
- NCT06977061
- Testing
- Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy
- Volunteers
- 30 people
- Sponsor
- Queling Liu
Hepatocellular Carcinoma (HCC)
SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
SBRT combined with dual PD-1/CTLA-4 blockade (iparomlimab and tuvonralimab, QL1706) and bevacizumab may provide complementary local and systemic antitumor activity in hepatocellular carcinoma (HCC).
- Trial name
- NCT07882056
- Testing
- Stereotactic Body Radiotherapy, Bevacizumab, Iparomlimab and Tuvonralimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking University Cancer Hospital & Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
The goal of this clinical trial is to evaluate the efficacy and safety of Endostar combined with Toripalimab in the adjuvant treatment of resectable stage III-oligometastatic stage IV melanoma, and to find effective biomarkers of…
- Trial name
- NCT05907512
- Testing
- Endostar, Toripalimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Breast Neoplasms, Bone Neoplasms
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
This is a prospective, observational pilot study that will describe the safety profile and biological effects of combining stereotactic ablative body radiosurgery (SABR) treatment (20Gy/1#) and a PD-1 antibody, MK-3475.
- Trial name
- BOSTON II (NCT02303366)
- Testing
- Stereotactic Ablative Body Radiosurgery (SABR), MK-3475
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer
- Trial name
- ACCEL (NCT06229366)
- Testing
- [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)
- Where
- 7 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Nasopharyngeal Carcinoma
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal…
- Trial name
- NCT05524168
- Testing
- SBRT, Camrelizumab, Gemcitabine
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
We intend to compare the efficacy and safety of immunotherapy plus stereotactic body radiotherapy at oligometastatic lesions and immunotherapy alone among patients with oligometastatic nasopharyngeal carcinoma whose primary…
- Trial name
- NCT04944914
- Testing
- camrelizumab, stereotactic body radiotherapy
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sun Yat-sen University
Anal Cancer, Locally Advanced Squamous Cell Carcinoma
Circulating Biomarkers in Patients With Anal Cancer Treated With Induction Chemotherapy
To investigate the prognostic and predictive value of plasma HPV (pHPV) prior, during and after induction chemotherapy (ICT) in locally advanced squamous cell carcinoma of the anus (SCCA) or synchronous metastatic SCCA patients…
- Conditions
- Anal Cancer, Locally Advanced Squamous Cell Carcinoma, Oligometastatic Disease, Circulating Tumor Cell
- Trial name
- NCT05233540
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Aarhus University Hospital
Prostate Cancer, Malignant Neoplasm of Prostate
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment.
- Conditions
- Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
- Trial name
- NCT06150417
- Testing
- Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer
Depending on the cohort of the study the diagnostic and prognostic accuracy and health economics considerations of [18F]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET) and/or circulating tumor cells in…
- Trial name
- NCT05245435
- Testing
- FDHT-PET Scan, liquid biopsies
- Where
- Austria
- Sponsor
- Medical University of Vienna
Metastasis, Metastatic Breast Cancer
The Impact of Radiotherapy on Oligometastatic Cancer
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR).
- Conditions
- Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT05933876
- Testing
- To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR)., To propose a diagnostic test to determine the effectiveness of SABR., To propose a diagnostic test for Oligometastatic Cancer (OC).
- Where
- 21 sites in Spain
- Volunteers
- 2,000 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Gastric Adenocarcinoma
Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer
Surgical resection of the primary tumour and treatment of the metastatic site in oligometastatic stage IV metastatic gastric adenocarcinoma enhances survival and improves quality of life with acceptable postoperative morbidity…
- Trial name
- SURGIGAST (NCT03042169)
- Testing
- Preoperative Chemotherapy, Surgery, Postoperative chemotherapy
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Lille